Success Metrics

Clinical Success Rate

50.0%

Based on 3 completed trials

Completion Rate

50%(3/6)

Active Trials

1(11%)

Results Posted

67%(2 trials)

Terminated

3(33%)

Phase Distribution

Ph phase_1

44%

Ph phase_2

33%

Ph phase_3

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

4(50.0%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(4)

Other(1)

Detailed Status

Terminated3

Completed3

unknown1

Withdrawn1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (50.0%)

Phase 23 (37.5%)

Phase 31 (12.5%)

Trials by Status

unknown111%

terminated333%

completed333%

withdrawn111%

recruiting111%

Recent Activity

1 active trials

Showing 5 of 9

recruitingphase_3

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877

completedphase_2

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

NCT03422536

completedphase_1

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

NCT03316599

terminatedphase_2

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

NCT02318368

withdrawnphase_2

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

NCT04100330

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT06064877Phase 3

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting

NCT03422536Phase 2

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Completed

NCT03316599Phase 1

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Completed

NCT02318368Phase 2

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Terminated

NCT04100330Phase 2

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn

NCT02109627Phase 1

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Terminated

NCT02277197Phase 1

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed

NCT02277184Phase 1

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma